Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exploratory Trial to Assess Mechanism of Action, Clinical Effect, Safety and Tolerability of 12 Weeks of Treatment With BI 655130 in Patients With Active Ulcerative Colitis (UC)

Next Previous
Trial Profile

Exploratory Trial to Assess Mechanism of Action, Clinical Effect, Safety and Tolerability of 12 Weeks of Treatment With BI 655130 in Patients With Active Ulcerative Colitis (UC)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Spesolimab (Primary)
  • Indications Ulcerative colitis
  • Focus Pharmacodynamics; Pharmacogenomic
  • Sponsors Boehringer Ingelheim

Most Recent Events

  • 30 Oct 2019 Status changed from active, no longer recruiting to completed.
  • 23 Oct 2019 Planned End Date changed from 22 Oct 2019 to 24 Oct 2019.
  • 16 Sep 2019 Planned End Date changed from 28 Aug 2019 to 22 Oct 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top